Nanoparticle‐Mediated Intracellular Protection of Natural Killer Cells Avoids Cryoinjury and Retains Potent Antitumor Functions
Source abstract
Abstract
Abstract The ability of natural killer (NK) cells to mediate potent antitumor immunity in clinical adoptive transfer settings relies, in large part, on their ability to retain cytotoxic function following cryopreservation. To avoid potential systemic toxicities associated with infusions of NK cells into patients in the presence of dimethylsulfoxide (DMSO), interest in alternative cryoprotective agents (CPAs) with improved safety profiles has grown. Despite the development of various sugars, amino acids, polyols, and polyampholytes as cryoprotectants, their ability to promote protection from intracellular cryodamage is limited because they mostly act outside of the cell. Though ways to shuttle cryoprotectants intracellularly exist, NK cells' high aversity to manipulation and freezing has meant they are highly understudied as targets for the development of new cryopreservation approaches. Here, the first example of a safe and efficient platform for the intracellular delivery of non‐DMSO CPAs to NK cells is presented. Biocompatible chitosan‐based nanoparticles are engineered to mediate the efficient DMSO‐free cryopreservation of NK cells. NK cells cryopreserved in this way retain potent cytotoxic, degranulation, and cytokine production functions against tumor targets. This not only represents the first example of delivering nanoparticles to NK cells, but illustrates the clinical potential in manufacturing safer allogeneic adoptive immunotherapies “off the shelf.”
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Immune Cell Function and Interaction
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Industrial and Physical Pharmacy Purdue University West Lafayette IN 47907 USA
Center for Cancer Research Purdue University West Lafayette IN 47907 USA
References (67)
Show source-provided references
1. 10.1007/s11684-018-0653-910.1007/s11684-018-0653-9 ↗
2. 10.1016/j.jcyt.2014.09.00710.1016/j.jcyt.2014.09.007 ↗
3. 10.3389/fmed.2018.0015010.3389/fmed.2018.00150 ↗
4. 10.1096/fj.13-23544010.1096/fj.13-235440 ↗
5. 10.1016/j.bbmt.2012.11.46610.1016/j.bbmt.2012.11.466 ↗
6. 10.1038/bmt.2013.15210.1038/bmt.2013.152 ↗
7. Martino M. · Haematologica · 1996 · 81 · 59
8. 10.1159/00022726710.1159/000227267 ↗
9. Horacek J. M. · Exp. Oncol. · 2009 · 31 · 121
10. 10.1016/j.transci.2006.05.01910.1016/j.transci.2006.05.019 ↗
11. 10.1038/sj.bmt.170384810.1038/sj.bmt.1703848 ↗
12. 10.1080/1042819050023561110.1080/10428190500235611 ↗
13. 10.1038/bmt.2009.1310.1038/bmt.2009.13 ↗
14. 10.1002/2211-5463.1219310.1002/2211-5463.12193 ↗
15. 10.1371/journal.pone.015253810.1371/journal.pone.0152538 ↗
16. 10.1016/j.stemcr.2014.05.00310.1016/j.stemcr.2014.05.003 ↗
17. 10.1016/j.cryobiol.2007.05.00610.1016/j.cryobiol.2007.05.006 ↗
18. Singh M. · J Biotech Res. · 2017 · 8 · 78
19. 10.1006/cryo.1994.100110.1006/cryo.1994.1001 ↗
20. 10.1634/stemcells.2005-042710.1634/stemcells.2005-0427 ↗
21. 10.1038/s41598-018-33234-z10.1038/s41598-018-33234-z ↗
22. 10.1038/s41598-019-40660-010.1038/s41598-019-40660-0 ↗
23. 10.1007/BF0091522410.1007/BF00915224 ↗
24. 10.1016/0022-1759(80)90248-310.1016/0022-1759(80)90248-3 ↗
25. 10.1159/00023339710.1159/000233397 ↗
26. 10.1016/0022-1759(85)90041-910.1016/0022-1759(85)90041-9 ↗
27. 10.1016/j.bbmt.2014.05.00410.1016/j.bbmt.2014.05.004 ↗
28. 10.1016/j.jim.2014.01.01710.1016/j.jim.2014.01.017 ↗
29. 10.1007/s00432-016-2247-810.1007/s00432-016-2247-8 ↗
30. 10.1080/1465324090280703410.1080/14653240902807034 ↗
31. 10.1182/blood-2014-11-61031110.1182/blood-2014-11-610311 ↗
32. 10.3109/14653249.2012.70076710.3109/14653249.2012.700767 ↗
33. 10.1016/j.jcyt.2016.02.00810.1016/j.jcyt.2016.02.008 ↗
34. Torelli G. F. · Blood Transfus. · 2015 · 13 · 464
35. 10.1038/sj.bmt.170160910.1038/sj.bmt.1701609 ↗
36. 10.1089/ten.tec.2016.028410.1089/ten.tec.2016.0284 ↗
37. 10.1006/cryo.2001.235310.1006/cryo.2001.2353 ↗
38. 10.1016/S0006-3495(96)79407-910.1016/S0006-3495(96)79407-9 ↗
39. 10.1038/7260810.1038/72608 ↗
40. 10.1016/j.cryobiol.2014.04.00710.1016/j.cryobiol.2014.04.007 ↗
41. 10.1021/acsami.5b0065510.1021/acsami.5b00655 ↗
42. 10.1073/pnas.14231409910.1073/pnas.142314099 ↗
43. 10.1007/978-1-59745-362-2_310.1007/978-1-59745-362-2_3 ↗
44. 10.1128/AEM.61.10.3592-3597.199510.1128/AEM.61.10.3592-3597.1995 ↗
45. 10.1002/1097-0320(20011101)45:3<161::AID-CYTO1159>3.0.CO;2-710.1002/1097-0320(20011101)45:3<161::AID-CYTO1159>3.0.CO;2-7 ↗
46. 10.1016/j.theriogenology.2013.01.00210.1016/j.theriogenology.2013.01.002 ↗
47. 10.1016/j.cryobiol.2015.05.06310.1016/j.cryobiol.2015.05.063 ↗
48. 10.1016/j.bbamem.2016.03.02010.1016/j.bbamem.2016.03.020 ↗
49. 10.1002/btpr.239910.1002/btpr.2399 ↗
50. 10.1002/advs.20180204510.1002/advs.201802045 ↗
51. 10.1016/j.imlet.2017.09.01210.1016/j.imlet.2017.09.012 ↗
52. 10.1023/A:101212890722510.1023/A:1012128907225 ↗
53. 10.1021/acs.langmuir.8b0201510.1021/acs.langmuir.8b02015 ↗
54. 10.1023/A:102040461589810.1023/A:1020404615898 ↗
55. 10.1023/B:PHAM.0000003379.76417.3e10.1023/B:PHAM.0000003379.76417.3e ↗
56. 10.1016/j.ymthe.2017.06.01210.1016/j.ymthe.2017.06.012 ↗
57. 10.1155/2018/405481510.1155/2018/4054815 ↗
58. 10.1007/s00109-018-1679-910.1007/s00109-018-1679-9 ↗
59. CTL019 Out of Specification MAP for ALL or DLBCL Patients—Full Text View—ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03601442(accessed: October2019).
60. 10.1159/00049728910.1159/000497289 ↗
61. 10.1038/7258010.1038/72580 ↗
62. 10.3390/pharmaceutics904005310.3390/pharmaceutics9040053 ↗
63. Dao T. N. · Immunometabolism · 2019 · 1 · e190003
64. 10.1186/s40425-018-0441-810.1186/s40425-018-0441-8 ↗
65. 10.1016/j.jsps.2017.10.01210.1016/j.jsps.2017.10.012 ↗
66. 10.1248/cpb.58.142310.1248/cpb.58.1423 ↗
67. 10.3390/cancers1106076910.3390/cancers11060769 ↗